Responses
Clinical and epidemiological research
Concise report
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
Compose a Response to This Article
Other responses
No responses have been published for this article.